Biomarkers of Endothelial, Renal, and Platelet Dysfunction in Stage 5 Chronic Kidney Disease Hemodialysis Patients With Heart Failure
- PMID: 28990414
- PMCID: PMC6707716
- DOI: 10.1177/1076029617729216
Biomarkers of Endothelial, Renal, and Platelet Dysfunction in Stage 5 Chronic Kidney Disease Hemodialysis Patients With Heart Failure
Abstract
The aim of this study was to determine the role of endothelial, renal, and inflammatory biomarkers in the pathogenesis of heart failure (HF) in patients with stage 5 chronic kidney disease (CKD5) undergoing maintenance hemodialysis (HD). Plasma levels of biomarkers-kidney injury molecule 1 (KIM-1), N-terminal pro brain natriuretic peptide (NT-proBNP), glycated hemoglobin, neutrophil gelatinase-associated lipocalin, interleukin-18,platelet-derived growth factor, platelet factor 4 (PF4), 25-OH vitamin D, parathyroid hormone (PTH), endothelin, and endocan-were measured in CKD5-HD patients at the Loyola University Ambulatory Dialysis facility. The HF (+) CKD5-HD patients, as compared to HF (-) CKD5-HD patients, exhibited significantly elevated NT-proBNP ( P = .0194) and KIM-1 ( P = .0485). The NT-proBNP in HF (+) CKD5-HD patients was found to correlate with the levels of serum potassium ( P = .023, R = -.39), calcium ( P = .029, R = -.38), and PF4 ( P = .045, R = -.35). The KIM-1 in HF (+) CKD5-HD patients was found to correlate with PTH ( P = .043, R = -.36) and 25-OH vitamin D ( P = .037, R = .36). Elevated plasma NT-proBNP and KIM-1 in CKD5-HD and HF (+) CKD5-HD patients suggest that natriuretic peptides and KIM-1 may contribute to the pathogenesis of HF in CKD5-HD patients.
Keywords: HF; chronic kidney disease stage 5; hemodialysis; inflammatory biomarkers.
Conflict of interest statement
Similar articles
-
Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy.PLoS One. 2019 Sep 13;14(9):e0222547. doi: 10.1371/journal.pone.0222547. eCollection 2019. PLoS One. 2019. PMID: 31518378 Free PMC article.
-
NT-proBNP and troponin T levels differ after haemodialysis with a low versus high flux membrane.Int J Artif Organs. 2015 Feb;38(2):69-75. doi: 10.5301/ijao.5000387. Epub 2015 Mar 2. Int J Artif Organs. 2015. PMID: 25744196 Clinical Trial.
-
Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome.Eur J Heart Fail. 2016 Jun;18(6):641-9. doi: 10.1002/ejhf.426. Epub 2015 Oct 28. Eur J Heart Fail. 2016. PMID: 26511274
-
Pathophysiology and significance of natriuretic peptides in patients with end-stage kidney disease.Clin Biochem. 2020 Sep;83:1-11. doi: 10.1016/j.clinbiochem.2020.05.013. Epub 2020 Jun 5. Clin Biochem. 2020. PMID: 32511964 Review.
-
Natriuretic peptides in chronic kidney disease and during renal replacement therapy: an update.J Investig Med. 2009 Jan;57(1):33-9. doi: 10.2310/JIM.0b013e318194f44b. J Investig Med. 2009. PMID: 19158605 Review.
Cited by
-
Doctor-led intensive diet education on health-related quality of life in patients with chronic renal failure and hyperphosphatemia.World J Clin Cases. 2022 Feb 6;10(4):1217-1225. doi: 10.12998/wjcc.v10.i4.1217. World J Clin Cases. 2022. PMID: 35211555 Free PMC article.
-
Biomarkers in cardiorenal syndrome, a potential use in precision medicine.J Nephrol. 2024 Nov;37(8):2127-2138. doi: 10.1007/s40620-024-02047-x. Epub 2024 Aug 17. J Nephrol. 2024. PMID: 39153147 Review.
-
Hallmarks for Thrombotic and Hemorrhagic Risks in Chronic Kidney Disease Patients.Int J Mol Sci. 2024 Aug 9;25(16):8705. doi: 10.3390/ijms25168705. Int J Mol Sci. 2024. PMID: 39201390 Free PMC article. Review.
-
High circulating endocan in chronic kidney disease? A systematic review and meta-analysis.PLoS One. 2023 Aug 9;18(8):e0289710. doi: 10.1371/journal.pone.0289710. eCollection 2023. PLoS One. 2023. PMID: 37556458 Free PMC article.
-
Prognostic and Diagnostic Value of Endocan in Kidney Diseases.Int J Nephrol. 2022 Mar 14;2022:3861092. doi: 10.1155/2022/3861092. eCollection 2022. Int J Nephrol. 2022. PMID: 35321346 Free PMC article. Review.
References
-
- McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and HF: prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004;109(8):1004–1009. - PubMed
-
- Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive HF in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. 1995;47(3):884–890. - PubMed
-
- Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol. 2009;4(suppl 1):S79–S91. - PubMed
-
- Shiba N, Shimokawa H. Chronic kidney disease and HF—bidirectional close link and common therapeutic goal. J Cardiol. 2011;57(1):8–17. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous